

Synthesis of Heterocyclic Nitrogen Compounds using Cyclohexene Derivative with Various Primary Amines

Hamid J. Mohammad¹, Israa I. Salih², Rabeah T. Mahmood³

^{1,2,3} Department of Applied Chemistry, College of Applied Sciences, University of Samarra, Iraq
Email: hamid.jasim.m1987@gmail.com

ABSTRACT

Chalcones are famous compounds due to their mild reaction and acceptable yield, in addition to their pure products. The synthesized compounds in this study were prepared by two steps: step 1. Includes the reaction of chalcone and ethylacetoacetate to produce the previously prepared compound (cyclohexene derivative). Step 2. Includes the reaction of the last one with different primary amines to produce new compound by ring closure reaction. The identification of products based on IR, ¹³C-NMR.

Keywords: chalcone, ethyl acetoacetate, cyclohexene, primary amines.

Correspondence:

Hamid J. Mohammad

^{1,2,3} Department of Applied Chemistry, College of Applied Sciences, University of Samarra, Iraq

Email: hamid.jasim.m1987@gmail.com

INTRODUCTION

Chalcones are a family of aromatic ketones with two aromatic groups bridged by an enone linkage (Ar-COCH=CH-Ar) ⁽¹⁾. Furthermore, chalcones (trans-1,3-diaryl-2-propen-1-ones) are natural products belong to flavonoid, are considered as intermediate in the flavonoid's biosynthesis, and are widespread in plants. The existence of the α , β -unsaturated ketone moiety in chalcones is a common part found in a large number of biological active compounds. Therefore, chalcone derivatives from nature of synthetic origin exhibit diverse pharmacological activities, such as antimicrobial ⁽²⁾, antitumor ⁽³⁾, anticancer ^(4,5) and radical scavenger ⁽⁶⁾. Moreover, chalcones derivatives are screened for their anti-inflammatory activity ⁽⁷⁾. chalcones are readily prepared by aldol condensation of an aryl aldehyde with an acetophenone. The constituents that were chosen for the chalcone array included substituted aryl, including both 5-, and 6-membered ring heteroaryl, aldehydes and acetophenones ⁽⁸⁾. The condensation of α -diketones with vicinal diamines (including subsequent dehydrogenation) represents a classical method for the synthesis of pyrazines ⁽⁹⁾, especially symmetrically substituted ones. Chalcones act as precursors in the synthesis of numerous constructive compounds such as flavonoids and isoflavonoids ⁽¹⁰⁾. Flavonoids are the customary constituents of human diet. Chalcones comprise of a three carbon α , β -unsaturated carbonyl system. Condensation of aromatic aldehydes with acetophenones in the presence of catalyst yields chalcones ⁽¹¹⁾. Chalcones commence a diversity of chemical reactions together with the synthesis of pyrimidine, isoxazoles and Pyrazolines. Chalcones act as mediators in the synthesis of beneficial therapeutic compounds. Special attention has been given to chalcones due to their simple structures and diverse pharmacological activities. Worth mentioning activities of chalcones are in anti-inflammatory ⁽¹¹⁻¹⁴⁾, antifungal, antibacterial ⁽¹⁵⁾, antimalarial ⁽¹⁶⁻²⁰⁾, antitumor ⁽²¹⁾, antimicrobial ^(22,23), antiviral ⁽²⁴⁾, antitubercular ⁽²⁵⁾, antioxidant ⁽²⁶⁾, antimitotic ⁽²⁶⁾, anti-leishmanial ⁽²⁷⁾, anti-platelet ⁽²⁸⁾, anticancer ⁽²⁹⁾ and antihypertensive activities ⁽³⁰⁾. Owing to the above stated reasons, the synthesis of chalcones and chalcone based functionalized derivatives had remained primary objective. A number of techniques and schemes have been reported for the synthesis of these compounds. Amongst all the stated methods, Aldol condensation and Claisen-Schmidt condensation still hold

high position. The best method for the synthesis of chalcones is the conventional Claisen-Schmidt condensation in the presence of aqueous alkaline bases ⁽³¹⁾, Ba(OH)₂ ⁽³²⁾, LiOH, microwave irradiation and ultrasound irradiation ⁽³³⁾. Chalcones bearing maleimide are a class of organic compounds with numerous applications in synthetic chemistry ^(34,35), great attention has been oriented towards cyclic heterocyclic systems containing nitrogen, oxygen or sulfur atom, such class of compounds has wide applications ⁽³⁶⁻⁴⁰⁾, therefore we planned to synthesize some new five, six, and seven derivatives.

Experimental

Reagent and materials

All chemicals and solvents used of analytical reagent (A.R) grade quality and were used as received. Most of the chemicals were provided by United Tetragroup (Germany).

Apparatus measurements

Infrared (IR) spectra were recorded on Shimadzu FT-IR 8400S instrument and were calibrated using a polystyrene film. Solid compounds were recorded in potassium bromide disks (KBr). ¹³C-NMR were recorded on 500 MHz Bruker spectrometer instrument using dimethyl sulfoxide (DMSO-d₆) as a solvent solution, using tetramethylsilane (TMS) as an internal standard. Chemical shifts were quoted in parts per million (ppm) downfield from TMS.

Organic Preparations

preparation of Cyclohexene derivative (3).

This compound was prepared as previously reported ⁽⁴¹⁾. chalcone (1) (2.44 g, 0.01 mol) was mixed with ethyl acetoacetate (2) (1.5 ml, 0.01 mol) in ethanol (15 ml) and refluxed for 4 h, in the presence of (0.8 ml) 10% NaOH as a catalyst, The mixture was cooled to room temperature and the solid product obtained was filtered and recrystallized from ethanol, which gave white crystals of (3), m.p., 104-106 C° [Lit.104-106 C°]⁴¹ and (Yield: 3.35 g, 85%).

General procedure for the synthesis of the compounds (a, b, c, d, e).

A mixture of Cyclohexene derivative (3) (1 mol) in ethanol selected primary amines (1 mol) were refluxed, see Scheme (1). and monitored by TLC until reactions were completed. In each time, Reaction mixture was

cooled to room temperature, the resulting solid was collected by filtration, and recrystallized from ethanol, to give compounds (a, b, c, d, e), respectively. see table (1).

preparation of (f).

To a solution of hydroxylamine hydrochloride (0.21g, 1mol) in ethanol (5ml) containing pyridine (0.25 ml, 1mol) was added a solution of Cyclohexene derivative (3) (1g, 1mol) in ethanol (5ml), and the mixture refluxed for 4 h, and monitored by TLC until reaction was completed, the solvent was evaporated and the residue was taken in ethylacetate (10 ml), washed with a solution of sodium carbonate (15ml), and the organic layer was separated, dried over anhydrous $MgSO_4$. Solvent was evaporated, and the residue was recrystallized from ethanol, to give white crystals of (f).

Preparation of (a).

ν (KBr): 3030 (CH-aromatic.); 2970, 2890 (CH-aliph.); 1640, 1630 (C=N); 1600 (C=C); 1290 cm^{-1} (C-O). ^{13}C -NMR (DMSO- d_6): δ 31.1 (C_{8,24}); 45.7 (C_{9,17}); 74.0 (C₂₃); 116.1 (C₁₆); 126.1-129.4 (CH-aromatic.); 138.5 (C₁₀); 138.9 (C₅); 146.1 (C₇); 158.7 (C₁₈); 175.2 ppm (C₁₉). see Figure (1-4).

Preparation of (b).

ν (KBr): 3020 (CH-aromatic.); 2980, 2900 (CH-aliph.); 1650 (C=N); 1600 (C=C); 1525, 1334 (NO₂); 1325 (C-N); 1280 cm^{-1} (C-O). ^{13}C -NMR (DMSO- d_6): δ 31.1 (C_{8,30}); 45.7 (C_{9,17}); 74.0 (C₂₉); 116.1 (C₁₆); 126.1-129.4 (CH-aromatic.); 138.5 (C₁₀); 138.3 (C₅); 138.9 (C₂₆); 141.0 (C_{23,24}); 146.1 (C₇); 158.7 (C₁₈); 175.2 ppm (C₁₉).

Preparation of (c).

ν (KBr): 3040 (CH-aromatic.); 2985, 2890 (CH-aliph.); 1640 (C=O urea); 1625, 1620 (C=N); 1600 (C=C); 1260 cm^{-1} (C-O). ^{13}C -NMR (DMSO- d_6): δ 31.1 (C_{8,26}); 45.7 (C_{9,17}); 74.0 (C₂₅); 116.1 (C₁₆); 126.1-129.4 (CH-aromatic.); 138.5 (C₁₀); 138.9 (C₅); 146.1 (C₇); 155.3 (C₂₁); 175.2 ppm (C₁₉). 158.7 (C₁₈);

Preparation of (d).

ν (KBr): 3030 (CH-aromatic.); 2975, 2870 (CH-aliph.); 1630, 1625 (C=N); 1610 (C=C); 1250 cm^{-1} (C-O). ^{13}C -NMR (DMSO- d_6): δ 31.1 (C_{8,30}); 45.7 (C_{9,17}); 74.0 (C₂₉); 116.1 (C₁₆); 126.1-129.4 (CH-aromatic.); 137.6 (C₂₁); 137.9 (C₂₂); 138.5 (C₁₀); 138.9 (C₅); 146.1 (C₇); 158.7 (C₁₈); 175.2 ppm (C₁₉).

Preparation of (e).

ν (KBr): 3040 (CH-aromatic.); 2985, 2880 (CH-aliph.); 1640, 1635 (C=N); 1620 (C=C); 1230 cm^{-1} (C-O). ^{13}C -NMR (DMSO- d_6): δ 31.1 (C_{8,26}); 44.2 (C₂₁); 45.7 (C_{9,17}); 50.3 (C₂₂); 74.0 (C₂₅); 116.1 (C₁₆); 126.1-129.4 (CH-aromatic.); 138.5 (C₁₀); 138.9 (C₅); 146.1 (C₇); 158.7 (C₁₈); 175.2 ppm (C₁₉).

Preparation of (f).

ν (KBr): 3010 (CH-aromatic.); 2990, 2880 (CH-aliph.); 1680 (C=N); 1610 (C=C); 1285 cm^{-1} (C-O). ^{13}C -NMR (DMSO- d_6): δ 31.1 (C_{8,24}); 45.7 (C₉); 52.4 (C₁₇); 74.0 (C₂₃); 79.1 (C₁₈); 116.1 (C₁₆); 126.1-129.4 (CH-aromatic.); 138.5 (C₁₀); 138.9 (C₅); 146.1 (C₇); 175.2 ppm (C₁₉).

H-55
C13




Figure (1).



The University of Jordan
Faculty of Science
Department of Chemistry

Instrument Model:
Bruker 500 MHz-Avance III

Operator: Rola Hassouneh
nmr500@ju.edu.jo

Current Data Parameters
NAME 18oct01jalal
EXPNO 642
PROCNO 1


F2 = Acquisition Parameters
Date_ 20181004
Time 14.37
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg30
TD 65536
SOLVENT DMSO
NS 46
DS 4
SWH 31250.000 Hz
FIDRES 0.476837 Hz
AQ 1.0485760 sec
RG 202.06
DW 16.000 usec
DE 6.50 usec
TE 298.0 K
D1 2.0000000 sec
D11 0.0300000 sec
TD0 1

===== CHANNEL f1 =====
SFO1 125.7713681 MHz
NUC1 13C
P1 9.80 usec
PLW1 93.32499695 W

===== CHANNEL f2 =====
SFO2 500.1320005 MHz
NUC2 1H
CPOPRG2 waltz16
PCPD2 80.00 usec
PLW2 17.37800026 W
PLW12 0.36307999 W
PLW13 0.22982000 W

F2 = Processing parameters
SI 32768
SF 125.7577890 MHz
WDW EM
SSB 0
LB 1.00 Hz

H-55
C13



The University of Jordan
Faculty of Science
Department of Chemistry

Instrument Model:
Bruker 500 MHz-Avance III

Operator: Rola Hassounh
nmr500@ju.edu.jo

Current Data Parameters
NAME 18oct01jalal
EXPNO 642
PROCNO 1

F2 - Acquisition Parameters
Date_ 20181004
Time 14.37
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg30
TD 65536
SOLVENT DMSO
NS 46
DS 4
SWH 31250.000 Hz
FIDRES 0.476837 Hz
AQ 1.0485760 sec
RG 202.06
DM 16.000 usec
DE 6.50 usec
TE 298.0 K
D1 2.00000000 sec
D11 0.03000000 sec
TD0 1


CHANNEL f1
SFO1 125.7713681 MHz
NUC1 13C
P1 9.80 usec
PLW1 93.32499695 W

CHANNEL f2
SFO2 500.1320005 MHz
NUC2 1H
CPDPRG2 waltz16
PCPD2 80.00 usec
PLW2 17.37800026 W
PLW12 0.36307999 W
PLW13 0.22982000 W

F2 - Processing parameters
S1 32768
SF 125.7577890 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

Figure (2).

H-55
dept135



The University of Jordan
Faculty of Science
Department of Chemistry

Instrument Model:
Bruker 500 MHz-Avance III

Operator: Rola Hassounh
nmr500@ju.edu.jo

Current Data Parameters
NAME 18oct01jalal
EXPNO 643
PROCNO 1

F2 - Acquisition Parameters
Date_ 20181004
Time 14.39
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG dept135
TD 65536
SOLVENT DMSO
NS 30
DS 4
SWH 31250.000 Hz
FIDRES 0.476837 Hz
AQ 1.0485760 sec
RG 202.06
DM 16.000 usec
DE 4.50 usec
TE 298.0 K
CNST2 145.0000000
D1 2.00000000 sec
D2 0.00344828 sec
D12 0.00000000 sec
TD0 1

CHANNEL f1
SFO1 125.7704414 MHz
NUC1 13C
P1 9.80 usec
PLW1 93.32499695 W
SFO2 500.1315995 MHz
NUC2 1H
CPDPRG2 waltz16
P3 11.50 usec
P4 13.50 usec
PCPD2 80.00 usec
PLW2 17.37800026 W
PLW12 0.36307999 W

F2 - Processing parameters
S1 32768
SF 125.7577890 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

Figure (3).

H-55
dept135

 The University of Jordan
Faculty of Science
Department of Chemistry

 Instrument Model:
Bruker 500 MHz-Avance III

 Operator: Rola Hassouneh
nmr500@ju.edu.jo

 Current Data Parameters
NAME: 18oct01jalal
EXPNO: 643
PROCNO: 1

 F2 - Acquisition Parameters
Date_: 20181004
Time: 14.39
INSTRUM: spect
PROBHD: 5 mm PABBO 50/
PULPROG: zgpg30
TD: 65536
SOLVENT: DMSO
NS: 30
DS: 4
SWH: 31250.000 Hz
FIDRES: 0.474837 Hz
AQ: 1.0485760 sec
RG: 202.06
SW: 16.500 usec
DE: 6.50 usec
TE: 298.0 K
CHGT2: 145.0000000
D1: 2.00000000 sec
D2: 0.00344828 sec
D12: 0.00002000 sec
TDO: 1

 CHANNEL f1
SFO1: 125.7704414 MHz
NUC1: 13C
P1: 9.80 usec
P13: 2000.00 usec
PLA0: 0 W
PLA1: 93.32499695 W
SPHAI[5]: Crp40comp.4
SFOAL5: 0.500
SFOFF55: 0 Hz
SPW5: 13.49400024 W

 CHANNEL f2
SFO2: 500.1315995 MHz
NUC2: 1H
CPDPRG2: waltz16
P3: 11.50 usec
P4: 23.00 usec
PCPD2: 80.00 usec
PLA2: 17.37800056 W
PLA12: 0.34307999 W


 F2 - Processing parameters
S1: 20768
SF: 125.7577890 MHz
WDW: EM
SSB: 0
LB: 1.00 Hz
GB: 0
PC: 2.00



Figure (4).

Results and discussion

In this study, reactions between chalcone (1) and ethyl acetoacetate (2) in the presence of Sodium hydroxide as a catalyst and in refluxing ethanol as a solvent to give cyclohexene derivative (3), this compound was prepared as previously reported.⁴¹ because the importance of cyclohexene derivatives as biologically active agents, they are also useful synthons and building block for many heterocyclic products, so cyclohexene derivative (3) in

new step was reacted with various primary amines to give heterocyclic nitrogen compounds (a-f).

Heterocyclization of the new heterocyclic nitrogen compounds (a-f) was achieved by refluxing cyclohexene derivative (3) in ethanol without using any catalyst except compound (f) was need pyridine as a catalyst for the reaction to complete. see scheme (1). Formation of the products (a-f) was confirmed by IR, and ¹³C-NMR (DEPT 135).












R(a)= N, R(b)= N-ph(NO₂)₂, R(c)= N-CO, R(b)= N-ph, R(e)= NCH₂CH₂, R(f)= O



Scheme (1)

From this study, it was observed that yields were moderate to good. see table (1).

Table (1). primary amines that have been used, reaction time, some physical properties and yields of compounds (a-f).

Com.	primary amines	React time [hr]	Color	M.P C°	[%Yield]	
a	$\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$	2	Yellow	250	80	
b		9	Pink	263	40	
c	H_2NCONH_2	12	White	255	30	
d		10	Yellow	266	65	
e	$\text{H}_2\text{N}(\text{CH}_2)_2\text{NH}_2$	4	green	241	90	
f	$\text{NH}_2\text{OH} \cdot \text{HCl}$	4	white	247	80	

Conclusions


In conclusion, we have developed an exceedingly simple, mild and clean synthetic protocol for the synthesis of heterocyclic nitrogen compounds. This work describes the synthesis of new heterocyclic nitrogen compounds from reaction of cyclohexene derivative with various primary amines

Acknowledgments

The authors would like to thank the department of applied chemistry, college of applied sciences, university of samarra, Iraq, for providing the needed facilities.

Hamid J. Mohammad  : <https://orcid.org/0000-0003-3321-7858>

Israa I. Salih  : <https://orcid.org/0000-0002-3332-1762>

Rabeah T. Mahmood  : <https://orcid.org/0000-0001-8095-8531>

REFERENCES

1. Y. Rao, S.-H. Fang, Y.-M. Tzeng, Bioorg. Med. Chem., 2004, 12, 2679-2686.
2. Y. R. Prasad, P. R. Kumar, C. A. Deepti, M. V. Ramana, E-Journal of Chemistry, 2006, 3(13), 236- 241.
3. S. K. Kumar, E. Hager, C. Pettit, H. Gurulingappa, N. E. Davidson, S. R. Khan, J. Med. Chem., 2003, 46, 2813-2815.
4. J. Tatsuzaki, K. F. Bastow, K. Nakagawa-Goto, S. Nakamura, H. Itokawa, K.-H. Lee, J. Nat. Prod., 2006, 69(10), 1445-1449.
5. J.-M. Yun, M.-H. Kweon, H. Kwon, J.-K. Hwang, H. Mukhtar, Carcinogenesis., 2006, 27(7), 1454-1464.

6. B.-T. Kim, K.-J. O, J.-C. Chun, K.-J. Hwang, *Bull. Korean Chem. Soc.*, 2008, 29(6), 1125-1130.
7. Kim, Y. Hoon, Kim, Jeongsoo, Park, Haeil, Kim, H. Pyo, *Biol. Pharm. Bull.*, 2007, 30(8), 1450-1455.
8. D. G. Power, D. S. Casebier, D. Fokas, W. J. Rayan, J. R. Troth, D. L. Coffen, *Tetrahedron*, 1998, 54, 4085-4096.
9. Katritzky, A. R. *Handbook of Heterocyclic Chemistry*; Pergamon Press: Oxford, 1985; p. 432.
10. H. Avila, E. Smania, F. Monache, A. Junior, *Bioorg. Med. Chem.*, 2008, 16, 9790-9794.
11. Z. Nowakowska, *Eur. J. Med.Chem.*, 2007, 42(2), 125-137.
12. H. M. Yang, H. R. Shin, S. H. Cho, S. C. Bang, G. Y. Song, J. H. Ju, M. K. Kim, S. H. Lee, J. C. Ryu, Y. Kim, S. H. Jung, *Bioorg. Med. Chem.*, 2007 15(1), 104-11.
13. S. H. Lee, G.S. Seo, J. Y. Kim, X. Y. Jin, H. D. Kim, D. H. Sohn, *Eur. J. Pharmacol.*, 2006, 532(12), 178-186.
14. P. Rajendra, R. A. Srinivasa, R. Rambabu, *As. J. Chem.*, 2009, 21, 907-914.
15. Z. N. Siddiqui, S. Praveen, T. N. M. Musthafa, A. Ahmad, A. U. Khan, *J. Enz. Inhib. Med. Chem.*, 2012, 27(1), 84-91.
16. Valla, B. Valla, D. Cartier, R. Guillou, R. Labia, L., *Eur. J. Med.Chem.*, 2006, 41(1), 142-146.
17. J. Dominguez, C. León, J. Rodrigues, N. Domínguez, J. Gut, P. Rosenthal, *Farmacology*, 2005, 60(4), 307-311.
18. L. F. Motta, A. C. Gaudio, Y. Takahata, *Inter. Elect. J. Mol. Design.*, 2006, 5(12), 555-569.
19. J. Dominguez, J. Charris, G. Lobo, N. Gamboan, N. Dominguez, M. Moreno, F. Riggione, E. Sanchez, J. Olson, P. Rosenthal, *Eur. J. Med.Chem.*, 2001, 36(6), 555-560.
20. M. Liu, P. Wilairat, M. L. Go, *J. Med. Chem.*, 2002, 45(8), 1734.
21. W. Seo, Y. Ryu, M. Curtis-Long, C. Lee, H. Ryu, K. Jang, *Eur. J. Med.Chem.*, 2010, 45(5), 2010-2017.
22. V. Tomar, G. Bhattacharjee, Kamaluddina, A. Kumar, *Bioorg. Med. Chem. Lett.*, 2007, 17(19), 5321-5324.
23. Z. Nowakowska, B. Kedzia, G. Shroeder, *Eur. J. Med. Chem.*, 2008, 43(4), 707-713.
24. J. C. Trivedi, J. B. Bariwal, K. D. Upadhyay, E. D. Naliapara, S. K. Joshi, C. C. Pannecouque, E. D. Clercq, A. K. Shah, *Tetrahedron Lett.*, 2007, 48(48), 8472-8474.
25. Y. Lin, Y. Zhou, M. T. Flavin, L. Zhou, W. Nie, F. Chen, *Bioorg. Med. Chem.*, 2002, 10(8), 2795-2802.
26. R. Gacche, N. Dhole, S. Kamble, B. Bandgar, *J. Enz. Inhib. Med. Chem.*, 2008, 23(1), 28-31.
27. S. Ducki, R. Forrest, A. Hadfield Kendall, R. Lawrence, A. McGown, D. Rennison, *Bioorg. Med. Chem. Lett.*, 1998, 8(9), 1051-1056.
28. P. Boeck, C. Falco, P. Leal, R. Yunes, V. Filho, E. Torres-Santos, B. Rossi-Bergmann, *Bioorg. Med. Chem. Lett.*, 2006, 14(5), 1538-1545.
29. L. Zhao, H. Jin, L. Sun, H. Piao, Z. Quana, *Bioorg. Med. Chem. Lett.*, 2005, 15(22), 5027-5029.
30. M. Bonesi, M. Loizzo, G. Statti, S. Michel, F. Tillequin, F. Menichini, *Bioorg. Med. Chem. Lett.*, 2010, 20(6), 1990-1993.
31. Y. Rajendra Prasad, A. Lakshmana Rao, R. Rambabu, P. Ravi Kumar, *Oriental J. Chem.*, 2007, 23, 927-937.
32. M. Srinivasa Rao, J. Kotes, R. Narukulla, H. Duddeck, *Arkivoc*, 2004, xiv, 96-102.
33. V. Calvino, M. Picallo, J. Lopez-Peinado A, M. Martín-Aranda R, J. Durán-Valle C, *Appl. Surf. Sci.*, 2006, 252, 6071-6074.
34. S. Ad-Daraji and A. S. Hamad, *J. Chem. Chem. Eng.*, 2014, (8), 1018-1025.
35. I. Salih and A. S. Hamad, *IJPSR*, 2016., 7(3), 961-967.
36. H. J. Mohammad, A. S. Hamad and R. T. Mahmood, *J. Pharm. Sci. & Res.*, 2019, 11(3), 1073-1077.
37. R. T. Mahmood, H. J. Mohammad and A. A. Khalaf, *J. Global Pharm. Technology.*, 2019, 11(3), 325-332.
38. (A) M. T. Al-Abbasee, H. J. Mohammad and M. K. Mawlood, *Indian J. Forensic Medicine & Toxicology.*, 2020, 14 (1), 303-309. (B) S. Hamad, and H. J. Mohammad, *J. Purity, Utility Reaction and Environment.*, 2015, 4 (1), 27-35.
39. S. Hamad, and H. J. Mohammad, *IJPSR.*, 2016, 7(1), 101-107.
40. S. Samshuddin, B. Narayana, B. K. Sarojini, H. S. Yathirajan and R. Raghavendra, *Der. Pharma. Chemica.*, 2012, 4(4), 1445-1457.